Sparfloxacin: Difference between revisions

Jump to navigation Jump to search
m (Protected "Sparfloxacin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Line 20: Line 20:
}}
}}
{{SI}}
{{SI}}
{{EH}}
 


'''Sparfloxacin''' (spar FLOX a sin), trade names '''Zagam®''' and '''Zagam Respipac''', is a [[fluoroquinolone]] [[antibiotic]] used in the treatment of bacterial infections.  Zagam is no longer available in the United States.
'''Sparfloxacin''' (spar FLOX a sin), trade names '''Zagam®''' and '''Zagam Respipac''', is a [[fluoroquinolone]] [[antibiotic]] used in the treatment of bacterial infections.  Zagam is no longer available in the United States.
Line 33: Line 33:


[[Category:Fluoroquinolone antibiotics]]
[[Category:Fluoroquinolone antibiotics]]
{{SIB}}
 


[[ja:ザガム]]
[[ja:ザガム]]

Revision as of 16:11, 20 August 2012

Sparfloxacin
File:Sparfloxacin.svg
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability92%
Protein binding45%
MetabolismHepatic glucuronidation
Cytochrome P450 system not involved
Elimination half-life16 to 30 hours
ExcretionFecal (50%) and renal (50%)
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H22F2N4O3
Molar mass392.41 g/mol

WikiDoc Resources for Sparfloxacin

Articles

Most recent articles on Sparfloxacin

Most cited articles on Sparfloxacin

Review articles on Sparfloxacin

Articles on Sparfloxacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Sparfloxacin

Images of Sparfloxacin

Photos of Sparfloxacin

Podcasts & MP3s on Sparfloxacin

Videos on Sparfloxacin

Evidence Based Medicine

Cochrane Collaboration on Sparfloxacin

Bandolier on Sparfloxacin

TRIP on Sparfloxacin

Clinical Trials

Ongoing Trials on Sparfloxacin at Clinical Trials.gov

Trial results on Sparfloxacin

Clinical Trials on Sparfloxacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sparfloxacin

NICE Guidance on Sparfloxacin

NHS PRODIGY Guidance

FDA on Sparfloxacin

CDC on Sparfloxacin

Books

Books on Sparfloxacin

News

Sparfloxacin in the news

Be alerted to news on Sparfloxacin

News trends on Sparfloxacin

Commentary

Blogs on Sparfloxacin

Definitions

Definitions of Sparfloxacin

Patient Resources / Community

Patient resources on Sparfloxacin

Discussion groups on Sparfloxacin

Patient Handouts on Sparfloxacin

Directions to Hospitals Treating Sparfloxacin

Risk calculators and risk factors for Sparfloxacin

Healthcare Provider Resources

Symptoms of Sparfloxacin

Causes & Risk Factors for Sparfloxacin

Diagnostic studies for Sparfloxacin

Treatment of Sparfloxacin

Continuing Medical Education (CME)

CME Programs on Sparfloxacin

International

Sparfloxacin en Espanol

Sparfloxacin en Francais

Business

Sparfloxacin in the Marketplace

Patents on Sparfloxacin

Experimental / Informatics

List of terms related to Sparfloxacin


Sparfloxacin (spar FLOX a sin), trade names Zagam® and Zagam Respipac, is a fluoroquinolone antibiotic used in the treatment of bacterial infections. Zagam is no longer available in the United States.

Sparfloxacin achieves a high degree of penetration into most tissues, except for the central .nervous system. Sparfloxacin is about 37- 45% protein boun;J) (Shimada et at., 1993; Montay,1996). Following a single 400-mg oral dose of sparfloxacin, the mean peak concentration in ~ cantharides-induced inflammatory fluid is 1.3 lA-g per ml after a mean duration of 5 h post-dose. ,J. Thus(overall sparfloxacin penetration into inflammatory fluid is 117% and the mean elimination half-life from this fluid is 19.7 h (Johnson et at., 1992). Skin penetration of sparfloxacin is.good with skin:plasma ratios of 1.00 at 4 h (time of peak plasma concentration) and 1.39 at 5 h. Following single oral doses of 100 or 200mg, concentrations in skin of 0.56 and 0.82-1.31 lA-g per g, respectively, can be expected (Nogita and Ishibashi, 1991 ). Sparfloxacin achieves excellent penetration into human polymorphonuclear leukocytes in vitro (Garcia et at., 1992). Sparfloxacin achieves high concentrations in respiratory and sinus tissues. Following an oral loading dose of 400 mg followed by 200 mg daily, mean concentrations of sparfloxacin (2.5 to 5 h after dosing) in bronchial mucosa, epithelial lining fluid and alveolar macrophages are 4.4 ug per g, 15.0 ug per ml and 53.7 ug per g, respectively. The mean sparfloxacin concentration in maxillary sinus mucosa, 2-5 h after a single 400-mg dose, is 5.8 ug/g (Wise and Honeybourne, 1996) Shimada et at. ( 1993) has summarized many of the studies published in J apanese regarding the tissue distribution of sparfloxacin. (iligh concentrations are achieved in sputu!J!, pleural fluid, skin, lung, prostate, gynecological tissues, breast milk aJ1d otolaryngological ti~sues. Salivary concentrations are 66-70% of plasma levels, while CSF penetration appears to be somewhat.limited with CSF:plasma concentration ratios of only 0.25-0.35. Sparfloxacin achieves concentrati<>ns in bile and gallbladder of 7.1- to 83-fold the concurrent serum levels;J In rabbits, sparfloxacin achieves very good penetration into the ocular vitreous (54% ), cornea (76%) and lens (36%) (Cochereau-Massin et at., 1993).

Sparfloxacin has a similar rate of adverse reactions as ciprofloxacin and other commonly used fluoroqumolones. In a review of 2081 adult patients participating in a Phase III clinical trial of sparfloxacin in community-acquired, lower respiratory tract infections, sparfloxacin (200- or 4O0-mg loading dose then 100 or 200mg daily; i.e. 200/100mg and 400/200mg) had a similar incidence of adverse events as the comparator agents (Rubinstein, 1996). The overall rates of drug-related adverse reactions for sparfloxacin 400/200mg versus comparators and 200/100mg versus the comparator (amoxycillin/clavulanic acid) were 13.7 versus 17.7%, and 9.5 versus 13.2%, respectively. However, many of these reported reactions were very minor; discontinua- tion of the antibacterial agent because of drug-related adverse reactions occured in 1.6 versus 1.6%, and 1) versus 1.1 %, respectively. Adverse reactions affecting the nervous system were reported in 5.7% of the sparfloxacin group, with insomnia and other sleep disorders the most common events. Phototoxicity was noted in 2.0% of sparfloxacin recipients, with the average delay in onset being 6.3 :t 4.5 days (range 1-14 days) after commencing sparfloxacin. Mostly this comisted of erythema on the face and hands which lasted an average of 6.4 :t 4.2 days. The incidence of phototoxicity associated with sparfloxacin appears to be higher than that observed with ciprofloxacin and ofloxacin but less than that reported for fleroxacin, pefloxacin, enoxacin and nalidixic acid. Most importantly, features of the hemolytic-uremic syndrome such as that associated with temafloxacin (p.II44) have not been reported (Ram say and Obershkova, 1974; Bowie et at., 1989; Davey, 1989; Wolf son and Hooper, 1991; Rubinstein, 1996).

Template:QuinoloneAntiBiotics th:สปาร์ฟลอกซาซิน

Template:WH Template:WikiDoc Sources